文献速递重症综合管理与镇静镇痛

重症患者早期使用右美托咪定镇静

Early Sedation with Dexmedetomidine in Critically Ill Patients.
PubMed 文献 · N Engl J Med · 2019-05-19
一句话结论ICU机械通气成人早期以右美托咪定作为唯一或主要镇静剂,90天死亡率与常规镇静相似,但需补充镇静剂且心动过缓和低血压更多。

SPICE III为开放标签随机试验,纳入ICU内机械通气不足12小时、预期次日仍需呼吸支持的危重成人4000例,随机接受右美托咪定作为唯一或主要镇静剂,或常规镇静(丙泊酚、咪唑安定或其他镇静剂),镇静目标为Richmond躁动-镇静评分-2至+1。改良意向性分析纳入3904例,90天全因死亡率右美托咪定组29.1%(566/1948)与常规镇静组29.1%(569/1956)相似,校正风险差0.0个百分点(95%CI -2.9至2.8)。右美托咪定组为达到目标镇静深度需补充丙泊酚(64%)、咪唑安定(3%)或两者(7%),且心动过缓和低血压更常见。

要点

  • ICU机械通气成人早期使用右美托咪定作为唯一或主要镇静剂,90天死亡率29.1%(566/1948),常规镇静组29.1%(569/1956),校正风险差0.0个百分点(95%CI -2.9至2.8)。
  • 右美托咪定组为达到目标镇静(RASS -2至+1),随机后前2天64%需补充丙泊酚、3%补充咪唑安定、7%两者均用。
  • 右美托咪定组心动过缓和低血压较常规镇静组更常见。
  • 常规镇静组以丙泊酚、咪唑安定或其他镇静剂作为主要镇静剂的比例分别为60%、12%、20%。

适用人群与场景

  • ICU内机械通气不足12小时的危重成人,且预期超过下一个日历日仍需呼吸支持。

诊断标准与关键阈值

  • 镇静目标为Richmond躁动-镇静评分(RASS,-5无反应至+4好斗)−2至+1(轻度镇静至不安)。

处置流程与药物剂量

  • 右美托咪定作为唯一或主要镇静剂,目标RASS −2至+1;为达到该镇静水平,随机后前2天可补充丙泊酚(64%)、咪唑安定(3%)或两者(7%)。
  • 常规镇静组使用丙泊酚、咪唑安定或其他镇静剂作为主要镇静剂,比例分别为60%、12%、20%。

研究设计与关键结果

  • 开放标签随机试验,纳入4000例ICU机械通气成人,从符合条件到随机化的中位间隔4.6小时。
  • 改良意向性分析纳入3904例,90天全因死亡率右美托咪定组29.1%(566/1948)vs 常规镇静组29.1%(569/1956),校正风险差0.0个百分点(95%CI -2.9至2.8)。
  • 右美托咪定组为达到目标镇静,随机后前2天补充丙泊酚64%、咪唑安定3%、两者7%;常规镇静组以丙泊酚、咪唑安定或其他镇静剂为主要镇静剂者分别占60%、12%、20%。
  • 右美托咪定组心动过缓和低血压更常见。

证据类型、等级与局限

  • 证据类型:开放标签随机对照试验(SPICE III,NCT01728558),由澳大利亚国家健康与医学研究委员会等资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对ICU机械通气不足12小时、预期次日仍需呼吸支持的成人,早期使用右美托咪定作为唯一或主要镇静剂,90天死亡率与常规镇静相似,但常需补充丙泊酚或咪唑安定才能达到RASS −2至+1,且心动过缓和低血压更常见。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Dexmedetomidine produces sedation while maintaining a degree of arousability and may reduce the duration of mechanical ventilation and delirium among patients in the intensive care unit (ICU). The use of dexmedetomidine as the sole or primary sedative agent in patients undergoing mechanical ventilation has not been extensively studied.

METHODS: In an open-label, randomized trial, we enrolled critically ill adults who had been undergoing ventilation for less than 12 hours in the ICU and were expected to continue to receive ventilatory support for longer than the next calendar day to receive dexmedetomidine as the sole or primary sedative or to receive usual care (propofol, midazolam, or other sedatives). The target range of sedation-scores on the Richmond Agitation and Sedation Scale (which is scored from -5 [unresponsive] to +4 [combative]) was -2 to +1 (lightly sedated to restless). The primary outcome was the rate of death from any cause at 90 days.

RESULTS: We enrolled 4000 patients at a median interval of 4.6 hours between eligibility and randomization. In a modified intention-to-treat analysis involving 3904 patients, the primary outcome event occurred in 566 of 1948 (29.1%) in the dexmedetomidine group and in 569 of 1956 (29.1%) in the usual-care group (adjusted risk difference, 0.0 percentage points; 95% confidence interval, -2.9 to 2.8). An ancillary finding was that to achieve the prescribed level of sedation, patients in the dexmedetomidine group received supplemental propofol (64% of patients), midazolam (3%), or both (7%) during the first 2 days after randomization; in the usual-care group, these drugs were administered as primary sedatives in 60%, 12%, and 20% of the patients, respectively. Bradycardia and hypotension were more common in the dexmedetomidine group.

CONCLUSIONS: Among patients undergoing mechanical ventilation in the ICU, those who received early dexmedetomidine for sedation had a rate of death at 90 days similar to that in the usual-care group and required supplemental sedatives to achieve the prescribed level of sedation. More adverse events were reported in the dexmedetomidine group than in the usual-care group. (Funded by the National Health and Medical Research Council of Australia and others; SPICE III ClinicalTrials.gov number, NCT01728558.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Shehabi Y, Howe BD, Bellomo R, et al. Early Sedation with Dexmedetomidine in Critically Ill Patients. N Engl J Med. 2019. PMID: 31112380. doi:10.1056/NEJMoa1904710

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。